Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A, Attalla S, Fortier AM, Sanguin-Gendreau V, Pan TC, Papavasiliou V, Lin NU, Hughes ME, Smith K, Park M, Tremblay ML, Chodosh LA, Jeselsohn R, Muller WJ. Gu Y, et al. Among authors: papavasiliou v. Nat Commun. 2024 Oct 24;15(1):9174. doi: 10.1038/s41467-024-53023-9. Nat Commun. 2024. PMID: 39448577 Free PMC article.
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
Nandi I, Smith HW, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, Zuo D, Nam S, Attalla SS, Kim SH, Lusson S, Kuasne H, Fortier AM, Savage P, Martinez Ramirez C, Park M, Katzenellenbogen JA, Katzenellenbogen BS, Muller WJ. Nandi I, et al. Among authors: papavasiliou v. J Clin Invest. 2023 Apr 3;133(7):e162324. doi: 10.1172/JCI162324. J Clin Invest. 2023. PMID: 36795481 Free PMC article.
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, Solymoss E, Bui T, Kuasne H, Papavasiliou V, Lee CG, Kamle S, Siegel PM, Elias JA, Park M, Muller WJ. Taifour T, et al. Among authors: papavasiliou v. Immunity. 2023 Dec 12;56(12):2755-2772.e8. doi: 10.1016/j.immuni.2023.11.002. Epub 2023 Nov 30. Immunity. 2023. PMID: 38039967 Free article.
Targeting fatty acid oxidation enhances response to HER2-targeted therapy.
Nandi I, Ji L, Smith HW, Avizonis D, Papavasiliou V, Lavoie C, Pacis A, Attalla S, Sanguin-Gendreau V, Muller WJ. Nandi I, et al. Among authors: papavasiliou v. Nat Commun. 2024 Aug 3;15(1):6587. doi: 10.1038/s41467-024-50998-3. Nat Commun. 2024. PMID: 39097623 Free PMC article.
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ. Ursini-Siegel J, et al. Among authors: papavasiliou v. Mol Cell Biol. 2007 Sep;27(18):6361-71. doi: 10.1128/MCB.00686-07. Epub 2007 Jul 16. Mol Cell Biol. 2007. PMID: 17636013 Free PMC article.
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ. Smith HW, et al. Among authors: papavasiliou v. Nat Commun. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4. Nat Commun. 2019. PMID: 31263101 Free PMC article.
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.
Attalla SS, Boucher J, Proud H, Taifour T, Zuo D, Sanguin-Gendreau V, Ling C, Johnson G, Li V, Luo RB, Kuasne H, Papavasiliou V, Walsh LA, Barok M, Joensuu H, Park M, Roux PP, Muller WJ. Attalla SS, et al. Among authors: papavasiliou v. Cancer Immunol Res. 2023 Sep 1;11(9):1184-1202. doi: 10.1158/2326-6066.CIR-22-0140. Cancer Immunol Res. 2023. PMID: 37311021
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin CW, Luus L, Kamoun WS, Ghasemi O, Sahagian GG, Muller WJ, Hendriks BS, Wickham TJ, Drummond DC. Dumont N, et al. Among authors: papavasiliou v. Nanomedicine. 2019 Apr;17:71-81. doi: 10.1016/j.nano.2018.12.010. Epub 2019 Jan 14. Nanomedicine. 2019. PMID: 30654182
55 results